Advertisement

NCCN Guidelines for Non–Small Cell Lung Cancer (Version 3.2022)
Posted: 05/23/2022 | By: Justine Landin, PhD

Question 1 of 5

Which of the following is FALSE regarding testing for molecular biomarkers in NSCLC?

Choose 1

A
Molecular testing is recommended for eligible patients with locally advanced NSCLC
B
Laboratories do not typically report alterations that are classified as tier IV
C
Broad molecular profiling includes biomarkers such as ALK, BRAF, NTRK 1/2/3, and RET
D
Molecular profiling helps to differentiate primary lung cancers from intrapulmonary metastases

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage